Tian Zhang, MD, MHS

Financial relationships

  • Attribution:
    Self
    Type of financial relationship:
    Grant Or Contract
    Ineligible company:
    Pfizer, Eli Lilly, Tempus, ALX Oncology, Exelixis, Merck, OncoC4, Exelixis, Bayer
    Topic:
    PI (research funding)
    Date added:
    03/22/2022
    Date updated:
    05/21/2025
  • Attribution:
    Self
    Type of financial relationship:
    Independent contractor
    Ineligible company:
    Pfizer, MJH Associates, Vaniam, Aptitude Health, PeerView, Clinical Care Options, Mashup Media, Dava Oncology
    Topic:
    Consultant
    Date added:
    03/22/2022
    Date updated:
    05/21/2025
  • Attribution:
    Self
    Type of financial relationship:
    Independent contractor
    Ineligible company:
    Merck, Exelixis, Sanofi-Aventis, Janssen, AstraZeneca, Pfizer, BMS, Eisai, Aveo Pharmaceuticals, Bayer, Eli Lilly, Novartis, Gilead, EMD Serono, Dendreon, Xencor
    Topic:
    Advisory Board
    Date added:
    03/22/2022
    Date updated:
    05/21/2025
Return to 109 Division Of Hem/Onc: Combined Modality Conference (121125)

 

**Disclaimer**

This Continuing Medical Education (CME) Learning Management System, Ethos, includes individuals designated as 'faculty' for CME purposes. Please note that the term 'faculty' refers solely to their role as a contributor/planner within a CME activity and does not imply any formal affiliation with UT Southwestern Medical Center (UTSW). The display of names and credentials is intended for educational purposes only and does not necessarily indicate a professional or academic relationship with UTSW. Participants are encouraged to verify the affiliations and credentials of faculty members independently if further clarification is needed.